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ABSTRACT
The metabolic syndrome (MetS) is a diagnosis that includes several clinical
criteria that indicate a higher than normal risk of developing cardiovascular disease.
Central adiposity is considered a risk factor for the MetS and is also associated with
increased mortality and morbidity. The use of ultrasonography (US) has made it possible
to measure the amount of visceral fat (VF) in a cost-effective and non-invasive manner as
opposed to computed tomography or magnetic resonance imaging. C-reactive protein
(CRP), an acute phase inflammatory marker, has been associated with increased risk for
cardiovascular disease and has been shown to have a relationship with VF levels. The
purpose of the study was to determine the relationship between VF, CRP, and the MetS.
Visceral fat, CRP, MetS risk factors were evaluated in 34 participants who were over the
age of 40. An ultrasound scan at the waist was conducted to determine VF levels by
placing the wand 1 cm to the right of the umbilicus and performing a 10 cm scan towards
the right hip. Waist circumference was measured at the superior portion of the iliac crest.
CRP, blood glucose, HDL cholesterol, and triglycerides (TG) were measured using a
blood analyzer. Pearson’s Correlations were conducted to determine the relationships
between VF, CRP, and MetS risk factors. All variables were tested with an alpha level of
p ≤ .05. There were significant positive correlations between CRP and VF (r = .34, p =
.05) and CRP and TG (r = .50, p < .002). The results indicate the use of US as a costeffective, non-invasive method of evaluating potential risk for increased inflammation as
well as the development of the MetS and may be a viable alternative to traditional
methods of measuring VF.
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Chapter 1
Introduction
The metabolic syndrome (MetS) is a series of clinical findings that when clustered
together, increases the risk of developing type 2 diabetes and cardiovascular disease
(Wilson, D’Agostino, Parise, Sullivan, & Meigs, 2005). Several organizations have
provided clinical definitions for the diagnosis of the MetS, but the definitions between
organizations differ (Grundy, Brewer, Cleeman, Smith, & Lenfant, 2004). The
components of a MetS diagnosis are elevated triglycerides (TG), decreased high density
lipoprotein cholesterol (HDL-C), hypertension, increased central obesity, and elevated
fasting glucose levels. These risk factors are all independently related to an increased risk
for cardiovascular disease, but the presence of the MetS increases the risk exponentially
more than simply combining the individual risk factors (Ford, 2005; Isomaa et al., 2001;
Malone et al., 2009). Individuals with the MetS also have an increased risk for
developing type 2 diabetes (Lorenzo, Okoloise, Williams, Stern, & Haffner, 2003;
Wilson et al., 2005). There is a smaller, but still significant increase in risk for
cardiovascular disease and cardiovascular mortality for those with the MetS (Chambers et
al., 2001; Isomaa et al., 2001; Ridker et al., 2003; Rutter, Meigs, Sullivan, D’Agostino, &
Wilson, 2004; Wilson et al., 2005).
Recent data suggests that between 23% - 35% of all adult Americans have the
MetS and approximately 40% of people over the age 60 have the diagnosis (Malone et
al., 2009). In November of 2007, the American College of Sports Medicine (ACSM), in
partnership with the American Heart Association, launched an initiative entitled Exercise
is Medicine. The purpose of the initiative is for health care providers to include physical
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activity as a vital sign during check-ups and to include physical activity as an avenue for
chronic disease prevention and/or treatment. Lakka et al. (2003) concluded that a
sedentary lifestyle and poor cardiorespiratory fitness led to an increase in risk for being
diagnosed with the MetS. The researchers found that the least fit participants were nearly
seven times more likely to have the MetS compared with the most fit participants (Lakka
et al., 2003). On top of this finding, Lakka et al., (2003) concluded that low levels of
moderate and vigorous physical activity were associated with the risk factors for the
MetS as well as other factors related to the MetS such as inflammatory markers.
The Exercise is Medicine initiative can have a significant economic impact, but is
dependent on allied health professionals and primary care givers committing to the core
tenet that exercise can prevent and treat many chronic diseases. In a study done on the
health care costs of the MetS, researchers compared the annual cost of health care for
those with or without MetS and also compared those with and without type 2 diabetes
(Boudreau et al., 2009). The total annual cost of health care is made up of four categories;
inpatient, primary care, outpatient, and pharmacy. For patients with the MetS, the average
cost for health care annually was $5,732 versus $3,581 for subjects without the MetS
(Boudreau et al., 2009). Additionally, the inpatient and pharmacy cost for those with the
MetS were double the cost of those without. Because there is a much greater risk for
developing type 2 diabetes in the presence of the MetS, understanding the health care
costs in patients with or without type 2 diabetes is also important. Those with type 2
diabetes had a much higher cost annually than those with the MetS at $6,038 (Boudreau
et al., 2009). Overall, there is a clear link between the MetS and increased health care
costs including even higher costs for those with the MetS and type 2 diabetes, thereby
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increasing the need for the most practical and direct method of detecting, preventing, and
treating the MetS.
There has been a relationship established between the MetS risk factors and Creactive protein (CRP), but it is traditionally been assessed using the National Cholesterol
Education Program Adult Treatment Panel III (NCEP ATPIII) definition. The
relationship between CRP and the MetS as defined by the World Health Organization
(WHO) is also defined in the literature. In the larger scale, cross-sectional studies
examining the relationship between CRP and the MetS, a strong correlation has been
shown establishing a link between CRP and the MetS. Within these studies not all MetS
risk factors were measured at the time of data collection and some factors were selfreported by participants (such as blood pressure). These studies also utilized waist
circumference, waist-to-hip ratio, or BMI to measure central obesity, but none of those
methods are able to differentiate between subcutaneous and visceral fat compartments.
This is of significance as visceral fat has been shown to be more metabolically active
than subcutaneous fat and has also been shown to be a stronger, more reliable predictor of
future cardiovascular and metabolic disease (Ibrahim, 2009).
There is a well-documented relationship between obesity and an increased risk for
metabolic and cardiovascular disease (Hamdy, Porramtikul, & Al-Ozairi, 2006; Ibrahim,
2009; Porter et al., 2009). Currently, approximately two out of three Americans are
overweight or obese according to BMI classifications, which has steadily increased over
the past 30 years (Low, Chew, & Deurenberg-Yap, 2009). Increased BMI creates an
immediate and significant impact on our health care system costs as the cost per person,
per year for someone who is overweight or obese ($498 and $1,630 respectively) is
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significantly higher than a normal weight person’s medical costs (Tsai, Williamson, &
Glick, 2010). Obesity costs account for approximately 5% of health care spending in the
United States (Tsai et al., 2010). Several studies suggest that central obesity is more
strongly associated with increased risks for metabolic and cardiovascular disease when
compared to total adiposity (Hamdy et al., 2006; Ibrahim, 2009; Liu et al., 2010; Smith et
al., 2012). Additionally, visceral fat has a stronger correlation to the risk factors for MetS
than that of subcutaneous fat even after the adjustment for weight (BMI; Liu et al., 2010).
The gold standards for measuring visceral fat are through computed tomography
(CT) scans or magnetic resonance imaging (MRI), which are expensive and difficult to
access for the general population. Recently, ultrasonography has been utilized and
validated as a method to measure visceral fat levels (Alempijevic et al., 2011; Gong et al.,
2007; Hirooka et al., 2005; Kim et al., 2004; Rolfe et al., 2010; Shojaei et al., 2010;
Stolk, Meijer, Mali, Grobbee, & Van Der Graaf, 2003; Stolk et al., 2001). The
relationship between visceral fat measured through ultrasonography have been compared
to visceral fat using CT (r = 0.82 - 0.86) and MRI (r = 0.77) with strong correlations
(Gong et al., 2007; Hirooka et al., 2005; Stolk et al., 2003). This comparison between the
gold standards of measuring visceral fat and ultrasonography lend validity to
ultrasonography as an alternative, accessible, and inexpensive measurement tool for
central obesity that is more practical for allied health professionals. Therefore, the use of
ultrasound to measure visceral fat as a replacement for waist circumference and other
anthropometric measures of obesity may provide a valid, practical, and cost-effective
measurement of central obesity in the definition of the MetS.
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Purpose Statement
The primary purpose of this study was to determine the relationship between
CRP, visceral fat, and the metabolic syndrome (MetS) risk factors.
Hypotheses
Ho: There will be no significant correlations between CRP and the MetS risk
factors.
Ha: There will be significant, positive correlations between CRP and the
following MetS risk factors: triglycerides, blood pressure, fasting glucose, and
visceral fat.
Ha: There will be a significant, negative correlation between CRP and HDL-C.
Operational Definitions
The Metabolic Syndrome: The clustering of three or more of the following risk
factors as defined by the National Cholesterol Education Program ATP III: elevated
triglycerides, hypertension, low levels of high density lipoprotein cholesterol, visceral
adiposity, and elevated fasting glucose. TG, HDL-C, and fasting glucose were measured
with a Cholestech LDX Analyzer. Blood pressure was measured using an aneroid
sphygmomanometer and waist circumference was measured with a Gulick tape measure.
The specific thresholds for each of the risk factors are as follows (Grundy et al., 2004):
Elevated TG. Characterized by blood TG levels >150 mg/dl.
Hypertension. Characterized by systolic blood pressure >130 mmHg and/or
diastolic blood pressure >85 mmHg.
Reduced HDL-C. Characterized by < 40 mg/dl of HDL-C for males and <50
mg/dl for females.
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Elevated waist circumference. Characterized by waist circumference >102 cm for
males and >88 cm for females.
Elevated (impaired) fasting glucose. Characterized by fasting glucose levels
>110 mg/dl.
Body Mass Index: Body mass index (BMI) is the ratio of height to
weight. The formula used for BMI in this study was weight in kilograms divided
by height in meters squared.
Assumptions
An important aspect of collecting the most accurate blood glucose and cholesterol
information is for the participant to be fasting for 10-12 hours before testing. It is
assumed that all participants followed this protocol to produce the most valid results
possible.
Delimitations and Limitations
The sample population for this study was delimited to older adults. For the
purpose of this study, those over the age of 40 were considered older adults. Also, the
sample size was delimited to 50 participants due to issues surrounding cost of equipment
and limited funding.
Significance
The importance of preventing the onset or the early detection and treatment of the
MetS is increasing as our population ages, becomes more sedentary, and more obese.
Currently, the estimates for Americans who have the MetS range from 23% - 35% with
this number reaching over 40% in those who are over the age of 60 (Malone et al., 2009).
By determining how CRP relates to the MetS risk factors in a relatively older population
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(older than 40) as well as exploring the relationship between CRP and visceral fat, allied
health professionals will gain important insight into potential methods of screening and
monitoring for MetS risk factors. The use of ultrasonography in the current study is also
significant because it may eliminate the need to use expensive, inaccessible methods of
measurement such as MRI or CT scans.
Overall, the goal of the study was to determine the most practical, cost-effective
method of identifying the MetS for the purpose of prevention, early detection, and early
treatment. Allied health professionals, along with primary care givers such as physicians,
are a crucial link to preventing the onset of chronic diseases such as the MetS, type 2
diabetes, and cardiovascular disease. In line with the Exercise is Medicine campaign,
equipping these professionals with the methods to better help their clients will only have
a favorable effect on the impact of chronic disease on their substantial health care costs.

Chapter 2
Review of Literature
Introduction
The purpose of this study was to determine the relationship between CRP, an
inflammatory marker, and the metabolic syndrome (MetS) risk factors using the NCEP
ATPIII definition while including visceral fat measurements through ultrasonography.
This chapter provides a review of the metabolic syndrome, visceral fat, and inflammation
as well as the interrelationships amongst them.
The Metabolic Syndrome
The metabolic syndrome (MetS) is characterized by a series of clinical findings
including hypertension, dyslipidemia, impaired glucose sensitivity, and visceral adiposity
and it is estimated that approximately one in four people in the United States are living
with the MetS (Wilson et al., 2005). People diagnosed with the MetS are at a higher risk
for developing type 2 diabetes as well as cardiovascular disease, which has a significant
economic impact in terms of health care costs. The burden of type 2 diabetes and
cardiovascular disease on United States health care costs is over $600 billion annually
(Rice, Cifelli, Pikosky, & Miller, 2011). More specifically, the health care costs for
individuals with and those without the MetS are substantially different. According to
Boudreau et al. (2009), health care utilization as well as costs was significantly greater in
patients with the MetS compared to patients without the MetS. Average annual total costs
for patients who had the MetS were 1.6 times higher than patients without the MetS
($5,732 vs. $3,581; Boudreau et al., 2009). Therefore, it is both in the best interest of
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individuals as well as the population as a whole to determine the most cost-effective,
practical methods of screening, preventing, and treating the components of the MetS.
For the purpose of this study, the most recent definition for MetS provided by the
NCEP ATPIII was used. There are other commonly used definitions, such as one defined
by the WHO. The two definitions are described below for the purpose of comparison as
they are the most commonly used in the MetS literature (Ford et al., 2005). The NCEP
ATP III definition was chosen for the current study as the WHO standards are difficult to
measure outside of a hospital or lab setting. The NCEP ATP III criteria are the most
easily measured and identified and the thresholds for the criteria are less stringent than
other definitions because having multiple risk factors that are marginal increases the risk
for cardiovascular disease (Grundy et al., 2004).
NCEP ATP III MetS definition. The current definition for the MetS in the
NCEP ATP III is the presence of any three (or more) of the following risk factors:
elevated TG, hypertension, reduced HDL-C, elevated waist circumference, and elevated
fasting glucose (Grundy et al., 2004).
WHO MetS definition. Defined as insulin resistance as classified by one of the
following: Type 2 diabetes, impaired fasting glucose, impaired glucose tolerance, or
those with glucose uptake below the lowest quartile for background population under
investigation under hyperinsulinemic or euglycemic conditions. Along with insulin
resistance, at least two of the following have to present as well: antihypertensive
medication and/or high blood pressure, elevated plasma triglycerides, elevated BMI
and/or waist to hip ratio, and elevated urinary albumin excretion rate or the
albumin:creatinine ratio (Grundy et al., 2004).
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The primary risk factors for the MetS have been strongly associated with risk for
developing type 2 diabetes using both the NCEP ATP III and WHO definitions (Bernard
et al., 2007; Ford, 2005; Hanson et al., 2002; Lorenzo et al., 2003; Rutter et al., 2004;
Wilson et al., 2005). Research has shown that several risk factors for type 2 diabetes are
strongly correlated with each other, which has led to the belief that they arise from
common factors (Hanson, Imperatore, Bennett, & Knowler, 2002). Obesity, central
adiposity, hypertension, insulin resistance, hypoalphalipoprotein, and
hypertriglyceridemia have been described as primary risk factors for type 2 diabetes and
because these risk factors are often clustered, it has been hypothesized that they stem
from a limited number of or a single metabolic abnormality (Hanson et al., 2002). Of the
aforementioned risk factors for type 2 diabetes, the combination of hypertension, insulin
resistance, dyslipidemia, and obesity fall into the definition for the MetS. Previous
research has shown that as the number of metabolic syndrome risk factors increases, the
higher the risk there is for developing type 2 diabetes (Wilson et al., 2005).
In addition to the individual MetS risk factors being associated with type 2
diabetes, there is an increased relative risk for developing type 2 diabetes for those with
the MetS (Ford, 2005; Hanson et al., 2002; Lorenzo et al., 2003; Wilson et al., 2005).
Throughout the research, there is consensus that there is an increased risk for type 2
diabetes, but the relative risk values differ. The range of relative risk for type 2 diabetes
in those who have the MetS is 1.5 to 17.9 (Ford, 2005; Hanson et al., 2002; Lorenzo et
al., 2003; Wilson et al., 2005). These relative risk values include research studies that
utilized both the NCEP ATP III definition and the WHO definition for the MetS, which is
important to note. The range presented is significantly large, but Ford (2005) performed a
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meta-analysis of studies that evaluated relative risk for type 2 diabetes in those with the
MetS and concluded that the NCEP definition yielded a collective relative risk of 2.99.
Much of the difference in relative risk values in the research can be attributed to the
definition of the MetS being used. Hanson et al. (2002) showed that the relative risk for
type 2 diabetes using the WHO definition was significantly higher than the relative risk
using the NCEP ATP III definition within the same population (3.58 & 2.09). This
difference in relative risk is credited to the fact that the WHO definition for the MetS
requires impaired fasting glucose plus two additional risk factors whereas the NCEP ATP
III definition simply requires any three risk factors (Hanson et al., 2002). The fact that the
NCEP ATP III definition treats all five risk factors equally and does not require impaired
fasting glucose for diagnosis plays a significant role in relative risk calculations for
predicting the development of type 2 diabetes compared to the WHO definition.
Impaired fasting glucose, a primary risk factor for the MetS, is diagnosed when
fasting blood glucose levels are greater than or equal to 110 mg/dL. The presence of
impaired fasting glucose very often precedes the onset of type 2 diabetes (Lorenzo et al.,
2003; Wilson et al., 2005). In a study done examining the MetS as a precursor of
cardiovascular disease and type 2 diabetes, the researchers found that having the MetS is
a good predictor of developing type 2 diabetes (Wilson et al., 2005). Within the same
research, an 8-year follow-up study, the researchers found that participants who only had
one component (impaired fasting glucose) of the MetS were at a much higher risk of
developing type 2 diabetes when compared to participants who had any one of the other
four MetS risk factors (Wilson et al., 2005). These results indicate that having impaired
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fasting glucose is a good predictor of a future type 2 diabetes diagnosis and is an
independent risk factor of incident type 2 diabetes.
The relative risk for type 2 diabetes for someone who only displays impaired
fasting glucose is significantly higher (12.5) than the relative risks for type 2 diabetes for
those who have elevated TG (2.9), hypertension (2.4), elevated waist circumference (4.1),
and low HDL-C (2.7; Wilson et al., 2005). These specific results indicate that the
appearance of the impaired fasting glucose risk factor for MetS has a larger impact on the
relative risk and prevalence of future type 2 diabetes diagnoses, as the relative risk for
non-impaired glucose fasting risk factors was three to five times lower (Wilson et al.,
2005).
For those who had two MetS components with one being impaired fasting
glucose, the relative risk for type 2 diabetes was two to three times higher than those who
had two MetS components without having impaired fasting glucose (Wilson et al., 2005).
Participants who had three MetS components, including impaired fasting glucose, also
had two to three times higher relative risk for type 2 diabetes (Wilson et al., 2005).
Interestingly, the relative risk for those with two compared to three MetS components
(both including impaired fasting glucose) was not significantly different, which is
important as it may indicate that any level of clustering of risk factors including impaired
fasting glucose shows a central insulin-resistant pathophysiology. Although participants
who showed the impaired fasting glucose component of MetS suffered from a higher
relative risk than those who did not, all participants who had any form of risk factor
clustering suffered from a higher relative risk.
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Individuals who have been diagnosed with the MetS are also at an increased risk
for developing cardiovascular disease (Chambers et al., 2001; Isomaa et al., 2001; Ridker
et al., 2003; Rutter et al., 2004; Wilson et al., 2005). The risk factors for the MetS have
all independently been linked to a greater risk for cardiovascular disease, but the presence
of MetS increases that risk even further (Ford, 2005; Isomaa et al., 2001; Malone et al.,
2009). The use of differing definitions of the MetS as well as different criteria within
each definition has led to an inconsistency in the numbers related to the relative risk of
cardiovascular disease for those with the MetS. In spite of these discrepancies, the
overwhelming consensus is that being diagnosed with the MetS increases the risk for
cardiovascular disease as well as cardiovascular mortality (Chambers et al., 2001; Ford,
2005; Isomaa et al., 2001; Malone et al., 2009; Ridker et al., 2003; Rutter et al., 2004;
Wilson et al., 2005).
Isomaa et al. (2001) suggests that the presence of the MetS was related to an
increase in cardiovascular disease, specifically coronary heart disease, acute myocardial
infarction, and stroke. The relative risk for coronary heart disease using the WHO
definition of the MetS was 2.96, whereas the risk for acute myocardial infarction was
2.63 and the risk for stroke was 2.27 (Isomaa et al., 2001). Using the NCEP ATPIII
definition of the MetS, it was shown that the relative risk for developing cardiovascular
disease ranged from 3.40 to 5.64 based on the number of MetS risk factors present (3-5
risk factors, respectively; Malone et al., 2009). Additionally, it was found that
dyslipidemia was associated with a higher risk for cardiovascular disease in patients with
type 2 diabetes and hypertension was associated with a higher risk in patients without
type 2 diabetes (Isomaa et al., 2001). In addition to being at a higher risk for
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cardiovascular disease, Isomaa et al. (2001) found that cardiovascular mortality was
increased in patients with the MetS compared to those without the MetS (12% v. 2%).
They also identified the combinations of obesity and hypertension and obesity and
dyslipidemia as the most common risk factor combinations, which are similar to the
findings of Malone et al., (2009).
Malone et al. (2009) proposes that the specific combination of risk factor
clustering is the most important factor for an increased risk of cardiovascular disease.
Malone et al. (2009) examined the specific combinations of risk factors and determined
that low HDL-C levels were present in the combinations with the highest relative risks
and that the combination of impaired fasting glucose, hypertension, and dyslipidemia
inferred the highest risk for cardiovascular disease of any of the combinations. Also, their
findings showed that hypertension was the greatest independent contributing risk factor
for increase in risk for stroke whereas low HDL-C was the greatest contributing risk
factor for the increase in risk for acute myocardial infarction (Malone et al., 2009). These
results are significant as low levels of HDL-C was a stronger risk factor than type 2
diabetes for acute myocardial infarction and stroke, but the clusters of risk factors that
contributed the most to increased risk of cardiovascular disease included both HDL-C
and impaired fasting glucose (Malone et al., 2009).
Although there are discrepancies in relative risk values for the MetS throughout
the literature and future risk for cardiovascular disease and mortality due to differing
definitions, there is a consensus that a relationship exists between the MetS and an
increased risk for cardiovascular disease and mortality (Chambers et al., 2001; Ford,
2005; Isomaa et al., 2001; Malone et al., 2009; Ridker et al., 2003; Rutter et al., 2004;
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Wilson et al., 2005). It also appears that the clustering of MetS risk factors contributes
more to an increased risk for cardiovascular disease and mortality than the individual
components of the MetS alone (Malone et al., 2009). Also, the specific clusters of risk
factors seems to play a significant role in the development of cardiovascular disease, with
the specific combination of impaired fasting glucose, dyslipidemia, and hypertension
inferring the highest risk (Malone et al., 2009).
Inflammation
There is a relationship between inflammatory markers, such as CRP, and
cardiovascular disease in both men and women (McLaughlin et al., 2002; Yudkin,
Stehouwer, Emeis, & Coppack, 1999). There is inconclusive evidence identifying the
cause of the inflammation and the exact role that it plays, but there are several hypotheses
for the etiology of the relationship between inflammation and cardiovascular disease.
Several epidemiological studies suggest that a strong relationship exists between
CRP and the MetS, however, it is not well understood (Frohlich et al., 2000; Kahn et al.,
2006; Ridker et al., 2003; Rutter et al., 2004; Wilson et al., 2005). A prominent theme is
that adipose tissue and the associated cytokines produced play a strong role. The primary
inflammatory markers that have been explored in relationship to cardiovascular disease
and the MetS are CRP, interleukin-6 (Il-6), and tumor necrosis factor alpha (TNFa;
Frolich et al., 2000). Il-6 and TNFa are both pro-inflammatory cytokines which are
directly related to levels of CRP, an acute phase inflammatory protein (Hak et al., 1999).
Adipocytes are the primary producer of TNFa within the human body and have
paracrine properties (Hak et al., 1999). The production of TNFa by adipose tissue leads to
the production of Il-6, which has endocrine properties and is a prime regulator of CRP

16

(Hak et al., 1999). According to Yudkin et al. (1999), blood concentrations as well as
production of Il-6 increases with increased adiposity and approximately 30% of
circulating Il-6 stems from adipose tissue. In the same study, the researchers identified a
statistically significant relationship between CRP and both Il-6 and TNFa (Yudkin et al.,
1999). TNFa also inhibits insulin-stimulated glucose uptake in cells and also plays a role
in decreasing lipoprotein lipase activity, which are important processes in the
development of several of the MetS risk factors (Frolich et al., 2000). The relationship
between the pro-inflammatory cytokines that are initiated by adipose tissue and CRP has
important implications for the development of the MetS.
Several studies investigating the relationship between the MetS and CRP have
suggested that the components of the MetS and the MetS itself are associated with an
inflammatory response (Frohlich et al., 2000; Kahn et al., 2006; Ridker et al., 2003;
Rutter et al., 2004). The stratification of CRP levels and the number of MetS risk factors
showed that there was a positive, statistically significant relationship between the two
(Frolich et al., 2000; Rutter et al., 2004). Also, researcher has shown that CRP levels
were higher among women than men in those with and without the MetS (Rutter et al.,
2004).
Researchers have been unable to identify the cause and effect relationship
between CRP and the MetS, but a clear relationship between the two has been identified
(Frohlich et al., 2000; Kahn et al., 2006; Ridker et al., 2003; Rutter et al., 2004; Wilson et
al., 2005). Additionally, recent research exploring the relationship between CRP and the
MetS has shown that CRP levels increase as the number of MetS risk factors increases
(Frolich et al., 2000; Rutter et al., 2004). Also of importance is the fact that the current
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research on the relationship between CRP and the MetS has been done using laboratory
testing and analysis for CRP (requiring a blood draw). Researchers in the current study
were only able to analyze CRP levels through a finger stick and a small amount of blood
by using the Cholestech LDX Analyzer.
Visceral Fat
Adiposity is classified as two different components based on primary storage site,
visceral fat and subcutaneous fat. Visceral fat is a specific type of adipose tissue that is
located around internal organs and is also known as intraabdominal fat. Visceral fat
accounts for 10-20% of total fat in males and 5-8% in females, making it far less
common than subcutaneous fat (Ibrahim, 2009). It has been shown that visceral fat has a
stronger correlation to the risk factors for MetS than that of subcutaneous fat and remains
so even after the adjustment for weight (BMI; Liu et al., 2010). Also, the use of these
common anthropometric measurements ignores the variability that is present between the
distribution of fat within ethnic groups as well as males and females. For example, it has
been shown that African-Americans have higher rates of obesity as defined by BMI than
European Americans, but have lower amounts of visceral fat (Liu et al., 2010). Similarly,
Nazare et al. (2012) showed that East Asians had lower BMI values but higher visceral
fat content than other ethnic groups.
There are anatomical and structural differences between visceral and
subcutaneous fat that are crucial to understanding the role they play in the development
of the MetS. One of the primary anatomical differences between visceral and
subcutaneous fat is the location of venous blood drainage. Subcutaneous fat has venous
drainage through systemic veins, which is in contrast to visceral fat venous drainage
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which occurs via the hepatic portal vein (Ibrahim, 2009). This is significant because the
portal drainage that occurs with visceral fat provides the liver with immediate access to
free fatty acids as well as adipokines. Adipokines are responsible for hepatic immune
mechanisms which produce important inflammatory markers such as CRP (Ibrahim,
2009).
The structural differences in visceral fat and subcutaneous fat have a significant
role in the development of the MetS. In general, adipose tissue is composed of a large
number of adipocytes as well as a variety of other non-fat cells such as macrophages and
immune cells (Ibrahim, 2009). A distinguishing difference in structure between visceral
fat and subcutaneous fat is the size of the adipocytes. The role of adipocytes within
adipose tissue is to store energy, which is in the form of triglyceride droplets. Research
has indicated that visceral fat contains a greater number of large adipocytes when
compared to subcutaneous fat, which contains a greater number of smaller adipocytes
(Ibrahim, 2009). This is important because when adipocytes get too large, they become
dysfunctional and are more resistant to insulin itself as well as to the anti-lipolytic effect
of insulin, which directly affects the development of the MetS (Ibrahim, 2009).
There have been a number of studies conducted to assess the predictive ability of
visceral and subcutaneous fat for cardiometabolic diseases (Fox et al., 2007; Liu et al.,
2010; Smith et al., 2012). The research indicates that correlations between visceral and
subcutaneous fat and the risk factors for MetS were statistically significant (Fox et al.,
2007; Liu et al., 2010; Smith et al., 2012). However, the correlations for visceral fat were
consistently stronger than the correlations for subcutaneous fat. Additionally, only
visceral fat correlations remained strong after adjusting for waist circumference and body
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mass index, which suggests that quantifying visceral fat provides more information than
anthropometric measurements provide (Fox et al., 2007; Liu et al., 2010). Also, research
has shown that visceral fat is correlated to future risk for cardiovascular disease (Smith et
al., 2012). Results from these studies indicate that visceral fat is better correlate to the
MetS than subcutaneous fat and gives more information regarding MetS risk factors than
common anthropometric measurements such as body mass index and waist
circumference. Furthermore, these studies suggest that the relationship between visceral
fat is stronger and more persistent than measures of subcutaneous fat when assessing
central obesity.
As well as being strongly correlated to the MetS risk factors, visceral fat has also
been shown to be strongly related to inflammatory markers such as CRP (Forouhi, Sattar,
& McKeigue, 2001; Khera et al., 2009; Lemieux et al., 2001; Park et al., 2010; Saijo et
al., 2004). These correlations were found in a variety of populations, including
Canadians, Europeans, South and East Asians as well as in overweight and obese
populations (Forouhi et al., 2001; Khera et al., 2009; Lemieux et al., 2001; Park et al.,
2010; Saijo et al., 2004). The relationship between CRP and visceral fat suggests that
visceral fat is an important contributor to chronic inflammation, especially in those who
are overweight or obese (Forouhi et al., 2001; Khera et al., 2009; Lemieux et al., 2001;
Park et al., 2010; Saijo et al., 2004). It is important to note that these correlations between
the MetS and visceral fat were obtained primarily through the use of CT. There is a lack
of scientific data that shows the relationship between visceral fat measured through
ultrasonography and CRP levels.
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Visceral Fat Measurement
Body composition methodology and risk identification has traditionally been in
the form of hydrostatic weighing and more recently air displacement plethysmography.
However, these forms of measuring body composition fail to account for different fat
compartments and just report an overall amount or percentage of fat. Octopolar
bioelectrical impedance devices have the ability to measure fat amounts in different
regions of the body including the trunk, but fail to differentiate between subcutaneous
and visceral fat. Similarly, external anthropometric methods of assessing abdominal
obesity such as waist circumference and waist-to-hip ratio are unable to differentiate the
fat compartments.
Both the NCEP ATPIII and the WHO definitions for the MetS utilize the
following anthropometric measurements to evaluate obesity: BMI, waist-to-hip ratio, and
waist circumference (Grundy et al., 2004). These anthropometric measurements are
commonly utilized because of their cost-effectiveness and ease of use, but fail to
differentiate fat compartments (visceral vs. subcutaneous) or in the case of BMI, fail to
account for any sort of distribution of fat. Although these measurements are easy to
administer and are correlated with other measures of central obesity, they fail to
specifically account for the more harmful and metabolically active visceral fat tissue
(Taylor et al., 2010). It has been shown that central obesity is more strongly associated
with increased risks for metabolic and cardiovascular disease when compared to total
adiposity (Hamdy et al., 2006; Ibrahim, 2009; Liu et al., 2010; Smith et al., 2012). As
such, estimates of obesity within populations being studied as it relates to the MetS are
inconsistent and are heavily dependent on the definitions being used. Isomma et al.
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(2001) showed that obesity defined by waist-to-hip ratio was more common than obesity
defined by BMI classifications. The differences were not subtle as only 10% of males and
14% of females were classified as obese using BMI classifications whereas 76% of males
and 36% of females were classified as obese using waist-to-hip ratio classifications
within the same population (Isomma et al., 2001).
Currently, CT is considered one of the gold standards of measuring visceral and
subcutaneous fat compartments along with MRI techniques. Although these measurement
methodologies are the most direct way of differentiating the fat compartments, they are
also extremely expensive, non-portable, and can expose people to harmful radiation. The
use of ultrasonography to measure visceral and subcutaneous fat compartments may be a
more practical, cost-effective, and portable method. In addition to these benefits, the use
of ultrasonography has been shown to be a valid and reproducible method of measuring
visceral fat (Alempijevic et al., 2011; Gong et al., 2007; Hirooka et al., 2005; Kim et al.,
2004; Rolfe et al., 2010; Shojaei et al., 2010; Stolk et al., 2003; Stolk et al., 2001). The
use of ultrasonography has also been used in older populations (Rolfe et al., 2010) as well
as those with chronic disease (Shojaei et al., 2010) to measure visceral fat. Additionally,
it has been used to estimate risks for cardiovascular and metabolic diseases (Kim et al.,
2004). Stolk et al., (2003) utilized ultrasonography measurements of visceral fat and
showed that it was a better predictor of the MetS than the commonly used waist
circumference measurement, which is an important finding that was used for the
foundation of the current study. Although ultrasonography has been shown to be a valid
method of measuring visceral fat, it has been validated in settings with clinical grade
equipment and technicians which can be cost-prohibitive. Recently, an ultrasound
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machine has been produced for use by allied health professionals. This provides a more
cost-effective alternative to clinical ultrasound testing and needs to be validated against
the MetS risk factors.
Visceral fat is a more metabolically active fat depot (Ibrahim, 2009) and is more
strongly related to the MetS than subcutaneous fat (Fox et al., 2012; Fox et al., 2007; Liu
et al., 2010). Therefore, it is essential to differentiate the two fat compartments when
determining the relationship to the MetS rather than using common anthropometric
measurements. There is also a relationship between visceral fat and inflammatory
markers such as CRP, but they have only been established through the use of CT. The use
of CT and MRI are the gold standards for measuring different fat compartments, but both
have a high cost and can contribute to radiation exposure. The use of ultrasonography has
been proposed as a valid, reproducible technique to measure visceral fat in a variety of
populations and has strong correlations to measurements of visceral fat measured through
both CT and MRI techniques (Alempijevic et al., 2011; Gong et al., 2007; Hirooka et al.,
2005; Kim et al., 2004; Rolfe et al., 2010; Shojaei et al., 2010; Stolk, Meijer, Mali,
Grobbee, & Van Der Graaf, 2003; Stolk et al., 2001).

Summary
Reviewing the current literature it is apparent that the MetS is a strong risk factor
associated with elevated health care costs as well as two major lifestyle related diseases
type 2 diabetes and cardiovascular disease. The syndrome is strongly associated with the
level of visceral fat and inflammation and ultrasound appears to be an effective method to
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assess visceral fat. If that is the case it is possible that correlating a non-invasive measure
of visceral fat with inflammation may be used as method for diagnosis of MetS.

Chapter 3
Methods
The primary purpose of the current study was to determine the relationship
between CRP, visceral fat, and the MetS risk factors using a modified NCEP ATPIII
definition. This chapter provides a description of the methodology that was used to test
the hypotheses for the current study. More specifically, this chapter provides a
background of the participants, information on the instrumentation used, an overview of
the procedures, and a description of the statistical analyses performed.
Participants
This study was delimited to participants over the age of 40 and testing was limited
to a maximum of 50 participants. The participants were recruited through a variety of
methods including informational flyers, word of mouth, and referrals from in and around
the community.
Instrumentation
To conduct this study, the following variables were measured in each participant:
height, weight, age, sex, triglyceride levels, HDL-C, fasting blood glucose levels, blood
pressure, hip and waist circumference, visceral and subcutaneous fat, and CRP.
Demographic information was collected through an interview with each participant.
Blood pressure was measured with an aneroid sphygmomanometer (ADC
Diagnostix, Hauppage, NY) after being seated for at least five minutes. Height and
weight were measured by a physician’s scale (Cardinal Scale Manufacturing Co., Webb
City, MO) and stadiometer. Hip and waist circumference were measured with the use of a
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Gulick tape measure. TG, HDL-C, fasting blood glucose, and CRP was measured through
the use of a Cholestech LDX blood analyzer (Cholestech Corporation, Hayward, CA).
Visceral and subcutaneous fat levels were measured with a BodyMetrix (IntelaMetrix,
Inc., Livermore, CA) ultrasonography machine.
Procedure
This study was approved through the Institutional Review Board (IRB) at Eastern
Washington University. Once the study was approved through the IRB, participants were
recruited to participate in the study. Prior to participation, an informational meeting was
held for all potential participants to go over informed consent. Participants were given
24-48 hours to decide whether they wanted to participate after full disclosure of the study
had been given.
All testing was completed in the Human Performance Lab at Eastern Washington
University. Blood pressure was taken after the participant was seated for at least five
minutes. Participants’ height and weight were measured using a physician’s scale and
stadiometer. A finger stick blood sample using a sterile lancet was performed to analyze
TG, HDL-C, blood glucose, and CRP. TG, HDL-C, and blood glucose were measured in
one cassette (35 ml blood) and CRP was measured in a separate cassette (40 ml blood).
The two cassettes were then placed in the Cholestech LDX Analyzer for analysis.
Participants had their waist circumference measured through the use of a Gulick tape
measure, which was placed at the superior portion of the iliac crest for measurement. The
last procedure that participants went through was an ultrasound scan of their abdomen to
assess visceral and subcutaneous fat levels. The abdomen scan was performed by placing
the gelled wand 1 cm to the right of the umbilicus and slowly moving it three to four
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inches towards the hip while maintaining a perpendicular position to the surface of the
skin. The measurement depths for visceral and subcutaneous fat were not calculated by
the machine, so they were determined by the researchers utilizing the BodyMetrix
software. The different fat layers are not consistent throughout the body, so the depth
varied across the scan. Because of this, two researchers agreed on the greatest depth for
each participant.
Data was collected on a separate data collection sheet, void of any identifiers that
was later entered into a Microsoft Excel file before being imported into SPSS for
analysis. Participants had the option of receiving their results from all the tests that were
performed. Educational materials were also available for participants who wanted more
information about their results.
Analysis
Statistical analysis was performed using SPSS version 20 (SPSS Inc., Chicago,
IL). Data was screened for outliers as well as checked for normality. Descriptive
statistics were provided on all of the MetS risk factors and frequencies were run to
determine the number of participants with and without the MetS. To examine the
relationship between the MetS risk factors, visceral fat, and CRP, Pearson’s correlations
were utilized. T-tests were also used to identify any differences between groups. Alpha
levels were set at p ≤ .05 for all statistical tests.
Summary
Using the outlined procedures and methodology, the researchers were able to
address the primary purpose of the current study, which was to determine the relationship
between CRP, an inflammatory marker, and MetS risk factors. Conclusions drawn from
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the statistical analyses were used to further the understanding of the interrelationships
between CRP and MetS risk factors (including visceral fat).

Chapter 4
Results
Introduction
The purpose of this study was to determine the relationship between CRP,
visceral fat, and the MetS risk factors. This chapter provides a summary of the results of
the statistical analysis described in the previous chapter.
Descriptive Statistics
Forty-five participants were initially recruited for data collection. Five
participants were excluded from analysis due to the CRP samples not reacting. Of the
remaining forty participants, another five were excluded from the analysis due to missing
TG values. Additionally, one participant was excluded due to having an abnormally high
CRP value. The overall means and standard deviations for the remaining 34 participants
included in the analysis are summarized in Table 1 as well as the means and standard
deviations for those with and without the MetS. In this study, the NCEP ATP III
definition of the MetS was used as previously described. Participants who were taking
hypertension medication were considered positive for the BP risk factor, regardless of
their measured values. Similarly, participants who were taking medication for diabetes
were considered positive for the impaired fasting glucose risk factor, regardless of their
measured values.
MetS Risk Factor Distribution
Twenty-one percent (n = 7) of our sample population had the MetS. The most
common risk factor was increased BP (62%) while the least common was increased WC
(6%). A similar number of participants had impaired fasting glucose (38%) compared to
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those with elevated TG (32%). Low HDL occurred in only 18% of the participants in the
current study.
Table 1. Descriptive statistics of sample population (Mean ± SD)
Total
(n = 34)

With MetS
(n = 7)

Without MetS
(n = 27)

Age

57.47 ± 9.96

63.29 ± 8.36

55.96 ± 9.91

Weight (kg)

74.77 ± 13.58

75.40 ± 12.20

76.32 ± 14.13

Height (m)

1.70 ± 0.09

1.63 ± 0.08

1.71 ± 0.09*

Waist Circumference (cm)

88.37 ± 11.92

96.14 ± 9.58

86.35 ± 11.78

Visceral Fat Depth (mm)

17.44 ± 7.16

18.81 ± 10.32

17.08 ± 6.31

Systolic Blood Pressure (mmHg)

116.65 ± 9.06

123.71 ± 10.55

114.82 ± 7.85*

Diastolic Blood Pressure (mmHg)

75.88 ± 8.90

79.43 ± 12.53

74.96 ± 7.75

High Density Lipoproteins (mg/dL)

61.77 ± 19.44

51.14 ± 16.80

64.52 ± 3.43

102.88 ± 64.88

182.43 ± 51.21

82.26 ± 50.91**

98.82 ± 14.23

116.86 ± 16.28

94.15 ± 9.26**

1.46 ± 1.11

2.71 ± 1.37

1.14 ± 0.78**

Variable

Triglycerides (mg/dL)
Blood Glucose (mg/dL)
C-reactive protein (mg/L)

**p < .05, **p < .01
Pearson’s Correlations
Correlations between the MetS risk factors, visceral fat, and CRP are reported in Table 2.
Significant moderate correlations were found between CRP and TG (r = .50, p = .05). No
other MetS risk factors were found to be significantly correlated. There was a significant,
moderate correlation between CRP and visceral fat depth as measured by ultrasound (r =
.34, p = .05). There was a weak to moderate non-significant correlation between CRP
and FG (r = .31, p = .08), CRP and WC ( r = .29, p = .10), and CRP and systolic BP (r =
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.28, p = .11). Also, there were weak to moderate, non-significant correlations between
visceral fat and WC and visceral fat and systolic BP (r = .31, p = .07; r = .31, p = .08).
Table 2. Correlations between MetS risk factors, visceral fat, and CRP
WC

SPB

DPB

CRP

HDL

TG

VF

FG

WC

-

SBP

.42*

DBP

.07

.64**

CRP

.29

.28

.00

-

HDL

-.12

-.05

-.34

.09

TG

.40*

.42*

.29

.50**

-.09

-

VF

.31

.31

.18

.34*

.06

.12

FG

.38*

.11

-.03

.31

.01

.64**

-.07

-

LDL

.14

.15

.16

.21

-.38*

.32

-.10

.37

LDL

-

-

-

-

*p < .05, **p < .01
Summary
A significant correlation was found between CRP and visceral fat as well as
between CRP and TG. Non-significant weak to moderate correlations were found
between CRP and three MetS risk factors (BP, FG, and WC). There were also nonsignificant, weak to moderate correlations between visceral fat and WC and visceral fat
and systolic BP. Overall, 21% of the studied population had the MetS and BP was the
most common MetS risk factor while WC was the least common risk factor.

Chapter 5
Discussion
Introduction
The primary purpose of this study was to determine the relationship between
CRP, visceral fat, and the MetS risk factors. The following chapter discusses the results
of the current study as they relate to the current literature.
Summary of results
A total of 34 participants over the age of 40 were used in the analysis. In the
current study, 21% (n = 7) of the population had at least three risk factors, classifying
them as having the MetS. The frequency of the MetS in this population is slightly lower
than previously reported in the literature (23% - 35%; Malone et al., 2009).
CRP and visceral fat
A significant positive correlation was found between CRP and visceral fat as
measured through ultrasonography. These results are in accordance with previous studies
that have identified a relationship between CRP and visceral fat (Forouhi et al., 2001;
Lemieux et al., 2001; Park et al., 2010; Saijo et al., 2004; Stolk et al., 2003). Previous
studies have assessed the validity and reliability of using ultrasonography to measure
different fat compartments, but none of them included CRP measures in their
comparisons (Gong et al., 2007; Hirooka et al., 2005; Stolk et al., 2003).
Although CRP and visceral fat have been shown to have a positive relationship
the mechanism for this relationship is unclear. One suggested mechanism is related to the
cytokines produced by adipose tissue. Both IL-6 and TNFa are secreted by adipose tissue
as proinflammatory cytokines, which can stimulate the liver to produce larger quantities
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of CRP (Park et al., 2010). Visceral fat has been shown to be the more metabolically
active adipose tissue in terms of production of both IL-6 and TNFa when compared to
subcutaneous fat (Park et al., 2010).
Similar to previous findings in the literature, women in the current study exhibited
significantly higher amounts of CRP compared to men (1.90 vs. 0.77 mg/L; p = 0.002;
Park et al., 2010). Lear et al., (2003) also showed that women, independent of age, waist
to hip ratio, smoking, and alcohol consumption, had consistently higher CRP values
when compared to men. One possible explanation is women who have reduced amounts
of estrogen tend to have higher amounts of visceral fat (Spangenburg, Wohlers, &
Valencia, 2012). In the current study, the average age of women was 59.38 years old and
the majority of women tested were post-menopausal. A potential outcome of age and
menopausal status of women tested is reduced estrogen and increased visceral fat or
increased fat cell size, which may contribute to the statistically higher amounts of CRP in
women.
In the current study, a relationship between visceral fat and the MetS risk factors
was identified through the use of an ultrasonography tool, which found similar results of
Stolk et al., (2003). Of further note, Stolk et al., (2003) used a clinical grade
ultrasonography machine within a clinical setting, whereas the current study used an
inexpensive, consumer-grade, the BodyMetrix handheld ultrasonography wand that is
portable and compatible with most computers. Because the BodyMetrix ultrasound
machine produced similar results as a clinical-grade ultrasound machine as well as CT
and MRI scans, it has the potential to be used as a screening tool for those who are at risk
of the MetS. It may also be used by individuals or professionals to assess changes in the
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different types of fat (visceral and subcutaneous), which are known to have an influence
on CRP levels.
CRP and MetS risk factors
Associations between CRP and the components of a lipoprotein-lipid profile have
been identified in previous literature, yet TG was the only component with a significant
relationship in the current study (Lemieux et al., 2001). The significant relationship
between CRP and TG values may suggest that there is a link between inflammation and
the body’s ability to clear fat from the blood. A potential explanation of the relationship
between inflammation and fat clearance is the effect of the IL-6 cytokine. Approximately
30% of circulating IL-6 stems from adipose tissue in the body (Yudkin et al., 1999). In
addition to stimulating CRP production in the liver, IL-6 and TNFa also affect the
activity of lipoprotein lipase, which is the protein that is responsible for the breakdown of
lipoproteins (Lemieux et al., 2001).
There were also weak non-significant correlations between CRP and WC, CRP
and systolic BP, and CRP and blood glucose. These same relationships have been
identified as significant correlations in previous studies (Ridker et al., 2002). The lack of
significance in the current study may be attributed to the relatively small sample size
compared to the larger, epidemiological studies in which significance was found and also
the fact that only seven out of 34 participants had the MetS in the current study.
Future Research Directions
Further research should include a larger sample size to ensure that the correlations
persist. Also, technicians who utilize the BodyMetrix software should become
accustomed to the process ahead of time and screen each image before moving on to the

34

next participant, as the software does not allow the users to go back and track the
interfaces later. During data reduction, the interfaces on the ultrasound images from
several participants were difficult to identify, which may have led to inaccurate visceral
fat values. It may not be possible to produce images with easily identifiable interfaces,
but the technique can be improved upon for future research.
The validity of the BodyMetrix as compared to clinical grade ultrasound
machines using strict protocols should be explored. It would also be beneficial to validate
the BodyMetrix against the gold standards of CT and/or MRI scans of fat compartments.
These validations against the gold standards of measuring the different fat compartments
would strengthen the value of the BodyMetrix machine for use with clinical populations
as well as in research settings.
In order to explore a possible explanation for the relationship between CRP and
visceral fat through ultrasonography, it would be beneficial to include TNFa and IL-6
measurements as well. It has been proposed that these cytokines play a role in the
development of the MetS risk factors as well as elevated levels of CRP.
Finally, it is of future interest to determine if changes in the amounts of visceral
fat lead to a reduction in CRP levels over time. To assess this, an exercise protocol could
be established to target visceral fat loss and the BodyMetrix machine could be used to
identify changes in fat levels over the course of the experiment.
Conclusion
The results of the current study suggest that there is a relationship between
visceral fat and CRP. This finding suggests that elevated levels of visceral fat plays a role
in chronic inflammation. This relationship did not exist between WC, a crude
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measurement of visceral fat, and CRP, suggesting that more direct measurements of
visceral fat such as ultrasonography are more predictive of chronic inflammation. It has
been shown that chronic inflammation increases the risk for future cardiovascular
disease, which also gives weight to the potential use of the BodyMetrix ultrasonography
tool to detect changes in visceral fat levels over time.
To add to and strengthen the results of the current study, it is necessary to conduct
a study with a larger number of participants and to include the measurement of
proinflammatory cytokines such as IL-6 and TNFa. Also, exploring the reliability and
sensitivity of the BodyMetrix machine to detect changes in visceral fat over time may be
useful in showing that the machine can be used as a preventive tool for the MetS.
Implementing an exercise protocol targeted at visceral fat loss can help determine if a
change in fat levels will also lead to a reduction in CRP values over time. Finally, using
venous blood draws to assess lipid profiles, glucose, and CRP may be preferred as they
produce more sensitive results.
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Appendix 1: IRB Approval

To:
From:

Evan Hilberg, Department of Physical Education, Health and Recreation,
200 PEB
Sarah A.C. Keller, Chair, Institutional Review Board

Date:

February 21, 2013

Subject:

Expedited Review of Determining the Relationship Between C-Reactive
Protein and the Metabolic Syndrome Risk Factors (HS-4172)

The Institutional Review Board for Human Subjects' Expedited Review Committee has
reviewed your proposal to evaluate the use of handheld ultrasonography as a method in
the measurement of visceral fat as part of an assessment of cardiovascular risk and
compare it to the most common methods of estimating body composition (bioelectrical
impedance analysis and three site skin folds).
The Expedited Review Committee has approved your application subject to the
conditions noted below; a signed, approved copy of your application is enclosed.
Before you begin:
1. We will need a copy of the recruiting flyer that you will be distributing.
2. Is Dr. Peterson going to be available at EWU for training of technicians and
lifestyle counseling?
3. You may provide the results of your tests to the subjects if they want them but
as a student you may not provide them your analysis of their results. If they are to
receive any analysis or lifestyle counseling it must be provided by a professional
such as Drs. Peterson or Repovich or their own physician.
4. Is the health questionnaire you are using the Par-Q? If not will you please
provide us a copy of the instrument for our files.
Human subjects research approval granted by the IRB is good for one year from the date
of approval, to February 21, 2014. If research is to continue, with no substantial changes,
beyond that date, a renewal of IRB approval must be obtained prior to continuation of the
project (contact OGRD for procedure). If, subsequent to initial approval, a research
protocol requires minor changes, the OGRD should be notified of those changes. Any
major departures from the original proposal must be approved by the appropriate review
process before the protocol may be altered. A Change of Protocol application must be
submitted to the IRB for any substantial change in the protocol. The Director, Grant and
Research Development, or the Chair of the IRB will determine whether or not the
research must then be resubmitted for approval.
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If you have additional questions please contact me at 509-359-7039; fax 509-359-2474:
email: skeller@ewu.edu. It would be helpful if you would refer to HS-4172 if there were
further correspondence as we file everything under this number. Thank you.
cc:

R.Galm
J.Kawaguchi
W.Repovich
Graduate Office
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Appendix 2: Informed Consent

Informed Consent Form
"Determining the relationship between C-reactive protein and the metabolic syndrome
risk factors"
In partial fulfillment of Master's Thesis for Evan Hilberg
Principal Investigator
Evan Hilberg
1604 3rd Street Cheney, WA 99004
Recreation Dept.
541-760-5072
evanhilberg@gmail.com

Responsible Project Investigator
Wendy Repovich, Ph.D., FACSM
Physical Education, Health and
200 Physical Education Bldg.
Cheney, WA 99004-2476

Purpose and Benefits
Risk for metabolic and cardiovascular disease is assessed through several biometric
measures such as body composition, glucose, cholesterol, blood markers of
inflammation (C-Reactive Protein), blood pressure, physical activity and visceral fat.
The purpose of this study is to determine the relationship between c-reactive protein
and the metabolic syndrome.
Procedures
Participation in this study will require the following procedures:
1) A questionnaire regarding current physical activity levels will be completed.
2) Height and weight will be measured on a standard scale.
2) Hip and waist circumference will be measured using a measuring tape.
3) Blood pressure will be measured on my right arm.
4) A finger prick will be conducted to collect 6 drops of blood for Cholesterol, CReactive protein and blood glucose tests.
5) Body fat percentage will be measured using skin folds, ultrasonography and
bioelectrical impedance analysis as described below:
- Skin Fold: a small fold of skin will be measured by a trained investigator at
three sites: men- chest, abdomen and thigh and women- triceps, suprilium
(hip) and thigh.
- Ultrasonography: A dime-sized amount of ultrasound gel will be placed on
each site and the scan will be performed by moving the ultrasound wand
over the site – back and forth three or four times. The sites are the same for
skin folds: men- chest, abdomen and thigh and women- triceps, suprilium
(hip) and thigh.
- Bioelectrical Impedance Analysis: A machine (similar to a scale) will be
used to estimate body fat percentage by sending a small electrical current
through my body.
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7) Visceral Fat will be estimated by Ultrasonography. A dime-sized amount of
ultrasound gel will be placed on my abdomen and the scan will be performed by
moving the device back and forth three to four inches above the right hip.

Risk, Stress or Discomfort
There is a minimal risk of an allergic reaction to the ultrasound gel. Bruising can
occur from the skin folds, ultrasonography, blood pressure readings, and finger stick.
There is risk of an infection at the finger stick site. Body composition results may
cause some stress for certain individuals. Lifestyle counseling will be available for my
benefit at the time of the measurements if needed.
Inquiries
Any questions about the procedures used in this study are encouraged. If you have any
concerns, questions, or would like more information please contact Wendy Repovich or
Evan Hilberg prior to signing the informed consent form. We can be reached at (509)359-7960; wrepovich@ewu.edu and (541) 760-5072 evanhilberg@gmail.com
respectively.
Other Information
You are requested to not engage in an alternate training program or to alter your diet
while you are taking part in the study. If you have any concerns about your rights as a
participant in this research or any complaints you wish to make, you may contact Ruth
Galm, Human Protection Administrator, (509) 359-6567 or rgalm@ewu.edu.

Signature of Principal Investigator

Date

Subject Statement
My participation in this study is completely voluntary. I am free to refuse participation
and to stop at any point in this study. I understand the study procedures that I will
perform, and the possible risks that go along with the testing and training. Knowing all of
the risks and discomforts, and being allowed to ask questions that have been answered to
my satisfaction, I consent to take part in this study. I am not waiving my legal rights by
signing this form. I understand I will receive a signed copy of this consent form.

Signature of Participant

Date
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Appendix 3: Data Collection Sheet

Date
Demographics
Age

Sex

Physical Activity
Medications
Yes
No
Clinical Values
Time Fasted
CRP
TC

Subject ID#

Ht (in)

Wt
(lbs)

WaistCir

HipCir

Vig
Mod(min) (min)
HyperTen

Cholest Diabetes HRT

HDL-C

LDL-C

TG

FG

Body
Composition
Male/Female
Triceps/Chest
SupIliac/Abd
Thigh/Thigh

BP

Skin Folds
Trial 1
Trial 2

Bioeletrical Impedance
BF %
Trunk
%

Ultrasound
Trial 1

Ultrasound Measurements
BF%
VAT
SCAT
Total

Estrogen

Smoke
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Appendix 4: Health History Questions

Family History/Medication Questions:
•

•

Do you have a family history of myocardial infarction, coronary
revascularization, or sudden death?
o before 55 years of age in father or other male first degree relative (i.e.,
brother or son)
o before 65 years of age in mother or other female first degree relative
(i.e., sister or daughter)
Are you currently on any of the following medications?
o Hypertension
o Diabetes
o Cholesterol
o Hormone replacement therapy
o Estrogen
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